Hearts & Minds Blog

Key Insights from March 2018 ACC: CLEAR Outcomes Looking Even CLEARer After ODYSSEY – Updated ICER Cost-Effectiveness Analysis A Win for Patients and for the Bempedoic Acid Franchise

Tim Mayleben

President and Chief Executive Officer

Our Lipid Management Team attended the 67th Annual Scientific Session of the American College of Cardiology (ACC) in Orlando this past weekend.  As is tradition following one of the major cardiology meetings, we want to provide our key insights as they relate to Esperion and our bempedoic acid-based therapies. The standout this year was the presentation of top-line results from ODYSSEY Outcomes (ODYSSEY), a cardiovascular outcomes trial (CVOT) for the injectable PCSK9i, alirocumab, along with the announcement by the Institute for Clinical and Economic Review… more

Help with Understanding Liver Function Test Increases: From the Lipid Management Team

Tim Mayleben

President and Chief Executive Officer

We recently announced positive results from our first pivotal phase 3 study (Study 4 or the 048 study) of bempedoic acid.  This was a significant milestone for our Lipid Management Team on our path of developing, gaining approval for, and commercializing bempedoic acid and the bempedoic acid / ezetimibe combination pill.  I’m incredibly proud of our team! In Study 4, bempedoic acid lowered LDL-cholesterol by 28%, reduced hsCRP by 33% and was observed to be safe and well-tolerated in 269 ASCVD or high-CV risk patients… more

The History of LDL-Cholesterol with Dr. Antonio Gotto | Beyond Statins: The Future of Cholesterol Lowering Treatments

Tim Mayleben

President and Chief Executive Officer

Antonio M. Gotto, Jr., MD, DPhil

Dean Emeritus, Weill Cornell Medicine, and Provost for Medical Affairs Emeritus, Cornell University

In Part I and Part II of this series we explored the evolution of LDL-cholesterol: from the early days of its discovery to the statin era boom. Now, we sit down again with cardiovascular and lipids specialist, Dr. Antonio M. Gotto, Jr, for the third and final installment of “The History of LDL-Cholesterol” to get his perspective on the future of LDL-cholesterol lowering. Read on for highlights from our conversation on the evolution of cholesterol-lowering treatments; the implications of bempedoic acid-based therapies for physicians, patients… more

Reflecting on a Focused 2017 and Looking Ahead to a Transformational 2018

Tim Mayleben

President and Chief Executive Officer

The past year was marked by tremendous progress for our bempedoic acid-based franchise – perhaps most importantly the achievement of positive regulatory interactions in the U.S. together with continued over-achievement on clinical trial execution – and your support was critical to this success. As I look back on these accomplishments, I’m struck by the focus, determination, perseverance, and “grit” our team demonstrated by: Securing regulatory confirmation for the pathways to approval for an LDL-cholesterol lowering indication for both bempedoic acid and the bempedoic acid /… more

Delivering on the “Long Game”

Tim Mayleben

President and Chief Executive Officer

I was recently approached by STAT to answer, “How do you balance your long-term goals for your company with the short-term demands of investors?”  My immediate thought seemed obvious: you can’t!  In LDL-cholesterol lowering research and development, in particular, there is no way to balance our long-term timelines with the short-term orientation of many investors – and at Esperion, we don’t try to. Let me explain: clinical development programs for chronic LDL-cholesterol lowering drugs require time; long-term clinical studies of regulatory-submission quality are double-blind with… more